Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Midodrine vs Albumin for PICD in ACLF
NCT05240391Phase 3Completed
- Sponsor
- Asian Institute of Gastroenterology
- Start
- Feb 2021
- Primary completion
- May 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of midodrine in Paracentesis-Induced Circulatory Dysfunction (PICD) (2 arms), sponsored by Asian Institute of Gastroenterology. Primary endpoint: Prevention of Paracentesis induced circulatory disturbance at Day 6. Started Feb 2021; status: completed.
02
Drugs
midodrine
03
Conditions
Paracentesis-Induced Circulatory Dysfunction (PICD)
Beyond the preview
Go deeper on NCT05240391.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05240391.